On April 22, 2019, Vimedimex Medi – Pharma Joint Stock Company announces the resolution of the Annual General Meeting 2019 as follows:
- Approving the business result in 2018:
- Total revenue: 15,217,572,000,000 dongs
- Net revenue: 15,179,926,000,000 dongs
- Profit before tax: 46,729,000,000 dongs
- Approving the business plan in 2019:
- Total revenue: 15,674,099,000,000 dongs
- Profit before tax: 48,130,000,000 dongs
- Approving the report on the BOD activities in 2018 and plan for 2019
- Approving the report from the Supervisory Board and plan for 2019.
- Approving the audited financial statements in 2018.
- Approving the profit distribution in 2018:
- Undistributed profit after tax: 38,588,941,164 dongs
- Profit after tax of 2018: 33,035,442,799 dongs
- Reserve fund to supplement charter capital (5% PAT): 1,651,772,140 dongs
- Investment and Development fund (10% PAT): 3,303,544,280 dongs
- Reward and Welfare fund (7% PAT): 2,312,480,996 dongs
- Dividend (20%/par value): 30,880,536,000 dongs
- Remaining profit after tax : 440,607,748 dongs.
- Approving the remuneration of the BOD and Supervisory Board in 2019:
- Chairman of BOD: 40,000,000/person/month
- Deputy chairman of BOD: 40,000,000/person/month
- Member or BOD: 15,000,000/person/month
- Secretary of BOD: 15,000,000/person/month
- Head of Supervisory Board: 15,000,000/person/month
- Member of Supervisory Board: 10,000,000/person/month.
- Approving the selection of AASC Auditing Com Ltd is the auditing firm to audit financial statements in 2019.
- Approving to amend and supplement its charter and business lines.
- Approving the resignation of Mr. Nguyen Dac Quang as member of Supervisory Board for the period 2017 – 2022.
- Approving the additional election of Mrs. Nguyen Thi Thanh Lan as member of Supervisory Board for the period 2017 – 2022.